The FDA has approved Sanofi’s subcutaneous Sarclisa Escena in combination with standard-of-care regimens for patients with multiple myeloma across all existing indications of the intravenous formulation, making it the first anticancer treatment administered through an on-body injector.
Sarclisa Escena is administered through Sanofi’s on-body injector and is the first multiple myeloma treatment in the U.S. available through both an on-body injector and manual subcutaneous administration, according to a July 10 news release.
The approval was supported by the phase 3 Iraklia trial, which found Sarclisa Escena delivered similar efficacy, pharmacokinetics and safety as the intravenous formulation while reducing treatment time and infusion-related reactions. The objective response rate was 71.1% with subcutaneous Sarclisa plus pomalidomide and dexamethasone, compared with 70.5% for the intravenous regimen. Systemic administration reactions occurred in 1.5% of patients receiving the subcutaneous formulation versus 25% of those receiving intravenous therapy.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
